2022年11月7日~2022年11月13日の間に収集した論文情報を追加しました。(1/2)
①Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine D2-Based Pharmacological Class Effect Query Defined by FAERS.
薬理学的クラスエフェクトクエリーを用いたリスペリドン安全性プロファイル
対象DB:FAERS
②Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System.
ヒト化抗cgrpモノクローナル抗体製剤の安全性プロファイル
対象DB:FAERS
③Consolidated Overview of Notifiable Adverse Events in the U.S. President's Emergency Plan for AIDS Relief's Voluntary Medical Male Circumcision Program Through 2020.
アフリカ諸国男性割礼プログラム後の有害事象サーベイランス
対象DB:NAERS
④Linezolid and the risk of QT interval prolongation: A Pharmacovigilance Study of the Food and Drug Administration Adverse Event Reporting System.
リネゾリドと QT 間隔延長のファーマコビジランス研究
対象DB:FAERS
⑤Real-world study of antiresorptive-related osteonecrosis of jaw based on the US food and drug administration adverse event reporting system database.
抗骨吸収剤による顎骨壊死のリアルワールドスタディ
対象DB:FAERS
⑥Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system.
セマグルチドに関連する胃腸の有害事象ファーマコビジランス研究
対象DB:FAERS
⑦Skin cancer signal associated with phosphodiesterase inhibitors: gaining insight through the FDA pharmacovigilance database.
ホスホジエステラーゼ阻害剤に関連した皮膚癌のシグナル調査
対象DB:FAERS
⑧Optimizing Safety Surveillance for COVID-19 Vaccines at the National Pharmacovigilance Centre Lareb: One Year of COVID-19 Vaccine Experience.
LarebにおけるCOVID-19ワクチンの安全性サーベイランスの最適化研究
対象DB:EudraVigilance